HT-93

Cat.No.: CSC-C6232X

Species: Homo sapiens (Human)

Source: Blood; Peripheral Blood

Morphology: single cells growing in suspension

Culture Properties: suspension

Inquire for Price

Specification
Background
Scientific Data
Q & A
Customer Review

Cat.No.

CSC-C6232X

Description

Established in 1993 from the peripheral blood of a 66-year-old man with acute promyelocytic leukemia (AML FAB M3) at relapse; described to carry t(15;17) and t(1;12) leading to PML-RARA and ETV6-ARG fusion genes, respectively

Species

Homo sapiens (Human)

Source

Blood; Peripheral Blood

Recommended Medium

80% RPMI-1640 + 20% h.i. FBS

Culture Properties

suspension

Morphology

single cells growing in suspension

Karyotype

Human near-diploid karyotype; 46(44-46)<2n>XY, t(1;12)(q25;p13), der(2)t(1;2)(q25;q31), der(4)t(1;4)(q21;q25)t(1;12)(q25;p13), der(6)del(6)(p23)t(4;6)(q25;q23), t(15;17)(q22;q21); carries complex t(1;12) and t(15;17) rearrangements effecting ETV6-ABL2 and

Disease

Acute Promyelocytic Leukemia

Quality Control

Mycoplasma: negative PCR assay
Immunology: CD3 -, CD13 +, CD15 (+), CD19 -, CD33 +, CD34 +, HLA-DR -
Viruses: PCR: EBV -, HBV -, HCV -, HIV -, HTLV-I/-II -

Storage and Shipping

Frozen with 70% medium, 20% FBS, 10% DMSO at about 7 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen

Synonyms

HT93A; HT-93A; HT93

Citation Guidance

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

HT-93, HT93 or HT-93A is a human hematopoietic cell line created in 1993 from peripheral blood of a 66-year-old male patient suffering from acute promyelocytic leukemia (APL, FAB subtype M3) that relapsed. This cell line grows in suspension and has a moderate doubling time of about 48-50 hours. Cytogenetic analysis reveals that HT-93 has the chromosomal translocations t(15;17)(q22;q12) which results in the oncogenic fusion gene PML-RARA typical for APL, and t(1;12)(p34;q13) which leads to the ETV6-ABL2 fusion gene.

HT-93 cells are positive for CD33 antigen and CD34 antigen and negative for lymphoid-associated markers, suggesting that they represent immature leukemia cells of myeloid lineage. Expression of the two fusion genes make HT-93 an attractive tool to study leukemic transformation, signal transduction and chromosomal instability in acute leukemias.

HT-93 cells have been used to study many aspects of APL including its pathogenesis, retinoic acid-mediated differentiation and pharmacological target discovery for the development of treatments against leukemia caused by these fusion proteins. Moreover, HT-93 cells have been used as a model system to study hematopoietic cell differentiation, drug resistance and kinase signaling mediated by rearrangements of ABL2.

Association of Kinesin Family Member 2A with Increased Disease Risk, Deteriorative Clinical Characteristics, and Shorter Survival Profiles in Acute Myeloid Leukemia

Ding et al. explored KIF2A expression correlation with AML risk, clinical characteristics, and prognosis, and investigated KIF2A knockdown effects on AML cell activities in vitro.

Bone marrow samples from 176 AML patients and 40 healthy donors were analyzed by qPCR. KIF2A was elevated in AML patients and predicted increased disease risk (AUC: 0.793, 95%CI: 0.724-0.826), correlating positively with white blood cells, monosomal karyotype, and high-risk stratification. Kaplan-Meier analysis showed KIF2A negatively correlated with event-free and overall survival. In vitro studies showed that KIF2A mRNA expression was elevated in KG-1, HL-60, ME-1, and HT-93 cell lines compared to CD34⁺ cells (Fig. 1A). KIF2A protein expression was also increased in KG-1, HL-60, ME-1, and HT-93 cell lines compared to CD34⁺ cells (Fig. 1B). In conclusion, KIF2A showed potential to be a biomarker and treatment target in AML.

RT-qPCR experiments were carried out in triplicate, and western blot was performed once. — Fig. 1. RT-qPCR experiments were carried out in triplicate, and western blot was performed once (Ding T, Li J, *et al.*, 2021).

Ask a Question

Write your own review

You May Also Need

CM-1448Y

SuperCult® RPMI 1640 Medium

INQUIRY

CS-001Y

PremSera® FBS

INQUIRY

WILL-1

Description: Established in 2007 from the bone marrow mononuclear cells of an 82-year-old Japanese man with diffuse large B-cell lymphoma in the leukemic phase

Cat#: CSC-C0633 INQUIRY

View Product

TALL-1

Description: Established from the bone marrow of a 28-year-old man who developed the terminal leukemic phase of lymphosarcoma in 1976

Cat#: CSC-C0530 INQUIRY

View Product

KG-1

Description: This cell line was derived from the bone marrow aspirate of a 59 year old male with erythroleukemia that became acute myelogenous leukaemia.The cells form colonies in soft-agar in the presence of ...

Cat#: CSC-C8220L INQUIRY

View Product

L-82

Description: Established from the pleural effusion of a 24-year-old woman with recurrent anaplastic large cell lymphoma (ALCL); cells were described to clonally derive from T-lineage lymphoid cells and to be ...

Cat#: CSC-C0600 INQUIRY

View Product

SUP-HD1

Description: Established from a 37-year-old man at second (refractory/terminal) relapse of Hodgkin lymphoma (nodular sclerosing -> lymphocyte depleted/stage IIISA -> stage IV) after both combined chemo- and ...

Cat#: CSC-C0579 INQUIRY

View Product

MHH-CALL-4

Description: Established from the peripheral blood of a 10-year-old Caucasian boy with acute lymphoblastic leukemia (pre B-ALL) at diagnosis in 1993

Cat#: CSC-C0396 INQUIRY

View Product

For research use only. Not for any other purpose.